View Clinical

Discovery

Download PPT

Hit-to-Lead

Amidino-urea 8918
Weill Medical College of Cornell University, NIAID, NIH, DHHS
BRD4592
The Broad Institute
Sulfolane
GlaxoSmithKline
RNA Polymerase Inhibitors
Rutgers University
Inhibitors of isoprenoid biosynthesis
Inhibitors of DosRST signaling and persistence
Michigan State University
ATP Synthesis Inhibitors
TB Alliance, University of Auckland
Energy Metabolism Inhibitors
TB Alliance, University of Auckland
IMPDH Inosine monophosphate dehydrogenase inhibitors
Aston University, University of Birmingham, Tres Cantos GSK
Menaquinone Synthase Inhibitors
Colorado State University
Actinomycete metabolites
University of Illinois at Chicago, Myongji University
Malate Synthase Inhibitors
Texas A&M University
Adamantanids
University of Illinois at Chicago
Whole-Cell Hit-to-Lead
GlaxoSmithKline, TB Alliance
Novel hit-lead programs
Lilly TB Drug Discovery Initative
Whole Cell Hit-to Lead
TB Alliance, Sanofi

Lead Optimization

TB Respiratory Chain
CSIR-Institute for Microbial Technology (IMTech), Johnson & Johnson
LeuRS inhibitors
GlaxoSmithKline, Anacor Pharmaceuticals
PKS13 Inhibitors - TAM16
Texas A&M University
Benzofuroxan
São Paulo State University (UNESP)
DprE1 Inhibitors
Calibr, The Scripps Research Institute
Indolcarboxamides
TB Alliance
SPR-113
Kanury Rao, Sundeep Duggar
Indazoles
GlaxoSmithKline, TB Alliance
TL1 Inhibitors
Sequella
Ureas
Sanofi , TB Alliance
Pyrazinamide Analogs
TB Alliance/Yonsei University
Macrolides
TB Alliance, Sanofi
HMG-CoA Reductase Inhibitors
Generic

Pre-Clinical (Non-GLP)

JSF-3285
Rutgers University
NTB-3119
Institute of Materia Medica
CPZEN-45
Institute of Microbial Chemistry (BIKAKEN), Tokyo, Japan, Lilly TB Drug Discovery Initiative, NIAID, IDRI, Lilly, YourEncore